Page last updated: 2024-12-07

zymostenol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

zymostenol: RN given refers to (3beta,5alpha)-isomer; RN for cpd without isomeric designation not available 9/88 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

5alpha-cholest-8-en-3beta-ol : A cholestanoid that is 5alpha-cholestane substituted by a beta-hydroxy group at position 3. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID101770
CHEBI ID16608
SCHEMBL ID2513505
MeSH IDM0159328

Synonyms (35)

Synonym
5alpha-cholest-8(9)-en-3beta-ol
LMST01010096
(5alpha)-cholest-8-en-3beta-ol
CHEBI:16608
zymostenol
5alpha-cholest-8-en-3beta-ol
cholestenol
566-97-2
C03845
5alpha-cholesta-8-en-3beta-ol
cholest-8-en-3-ol
delta(8)-cholestenol
(3s,5s,10s,13r,14r,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-ol
cholest-8-en-3-ol, (3beta,5alpha)-
unii-l3gy707blc
l3gy707blc ,
.delta.8-cholestenol
dihydrozymosterol
5.alpha.-cholest-8-en-3.beta.-ol
3.beta.-hydroxy-5.alpha.-cholest-8(9)-ene
cholest-8-en-3-ol, (3.beta.,5.alpha.)-
SCHEMBL2513505
DTXSID30205162
AKOS030240714
cholest-8(9)-en-3beta-ol
5-alpha-cholest-8-en-3-beta-ol
3beta-hydroxy-8(9)-cholestene
(3beta,5alpha)cholestenol
cholesta-8(9)-en-3beta-ol
3beta-hydroxycholest-8(9)-ene
Q27101995
o8-cholesterol
(3beta,5alpha)-cholest-8-en-3-ol
CS-0062013
HY-113345
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
3beta-sterolA sterol in which the hydroxy group at position 3 has beta- configuration.
cholestanoidAny steroid based on a cholestane skeleton and its derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (36)

PathwayProteinsCompounds
Metabolism14961108
Metabolism of lipids500463
Metabolism of steroids111135
Cholesterol biosynthesis2249
Kandutsch-Russell pathway410
Steroid Biosynthesis2142
Smith-Lemli-Opitz Syndrome (SLOS)2142
CHILD Syndrome2142
Desmosterolosis2142
Chondrodysplasia Punctata II, X-Linked Dominant (CDPX2)2142
Lysosomal Acid Lipase Deficiency (Wolman Disease)2142
Ibandronate Action Pathway2143
Simvastatin Action Pathway2143
Pravastatin Action Pathway2143
Rosuvastatin Action Pathway2143
Alendronate Action Pathway2143
Hypercholesterolemia2142
Lovastatin Action Pathway2143
Zoledronate Action Pathway2143
Cerivastatin Action Pathway2143
Risedronate Action Pathway2143
Pamidronate Action Pathway2143
Fluvastatin Action Pathway2143
Atorvastatin Action Pathway2143
Cholesteryl Ester Storage Disease2142
Hyper-IgD Syndrome2142
Mevalonic Aciduria2142
Wolman Disease2142
Cholesterol metabolism with Bloch and Kandutsch-Russell pathways039
Kandutsch-Russell Pathway (Cholesterol Biosynthesis)930
Cholesterol biosynthesis with skeletal dysplasias014
Cholesterol metabolism214
Enterocyte cholesterol metabolism111
Cholesterol biosynthesis pathway in hepatocytes1137
cholesterol biosynthesis II (via 24,25-dihydrolanosterol)937
superpathway of cholesterol biosynthesis2178

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (20.00)18.7374
1990's3 (30.00)18.2507
2000's1 (10.00)29.6817
2010's2 (20.00)24.3611
2020's2 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.08

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.08 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index5.06 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.08)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (20.00%)5.53%
Reviews1 (10.00%)6.00%
Case Studies1 (10.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (60.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]